Insmed Announces Positive Top-Line Results from Phase 3 CONVERT Study of ALIS (Amikacin Liposome Inhalation Suspension) in Adult Patients with Treatment-Refractory Nontuberculous Mycobacte...
Insmed Incorporated (INSM)
Last insmed incorporated earnings: 4/30 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.insmed.com
Company Research
Source: GlobeNewswire
Study met primary endpoint of culture conversion (pPositive top-line results from global Phase 3 controlled study in patients with NTM, a rare, progressive, destructive lung infection Company plans to pursue accelerated approval and request priority reviewCompany to host conference call today at 8:30 am EDT BRIDGEWATER, N.J., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced top-line data from its Phase 3 CONVERT study. Top-Line Efficacy Data The global CONVERT study met its primary endpoint of culture conversion by Month 6 with statistical and clinical significance. The study demonstrated that the addition of ALIS to guideline-based therapy (GBT) eliminated evidence of NTM lung disease caused by MAC in sputum by Month 6 in 29% of patients, compared to 9% of patients on GBT alone (p Insmed plans to pursue accelerated approval of ALIS under subpart H
Show less
Read more
Impact Snapshot
Event Time:
INSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INSM alerts
High impacting Insmed Incorporated news events
Weekly update
A roundup of the hottest topics
INSM
News
- Insmed to Host First-Quarter 2024 Financial Results Conference Call on Thursday, May 9, 2024PR Newswire
- Insmed Incorporated (NASDAQ: INSM) is now covered by analysts at Truist Financial Co.. They set a "buy" rating and a $48.00 price target on the stock.MarketBeat
- Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at Barclays PLC from $37.00 to $40.00. They now have an "overweight" rating on the stock.MarketBeat
- What Makes Insmed (INSM) a Lucrative Investment? [Yahoo! Finance]Yahoo! Finance
- Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)PR Newswire
INSM
Earnings
- 2/22/24 - Miss
INSM
Sec Filings
- 4/1/24 - Form DEFA14A
- 4/1/24 - Form DEF
- 3/11/24 - Form 8-K
- INSM's page on the SEC website